6. Desarrollo y análisis de resultados
6.2. Material utilizado
Heuvel LP, et al. Cationic uremic toxins affect human renal proximal tubule cell functioning through interaction with the organic cation transporter. Pflugers Arch. 465, 1701-1714 (2013). 20. Jansen J, Schophuizen CM, Wilmer MJ, Lahham SH, Mutsaers HA, Wetzels JF, Bank RA, et al. A
morphological and functional comparison of proximal tubule cell lines established from human urine and kidney tissue. Exp Cell Res. 323, 87-99 (2014).
21. Mutsaers HA, Wilmer MJ, Reijnders D, Jansen J, van den Broek PH, Forkink M, Schepers E, et al. Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration. Biochim Biophys Acta. 1832, 142-150 (2013).
22. Schirris TJJ, Jansen J, Mihajlovic M, van den Heuvel LP, Masereeuw R, Russel FGM. Mild intracellular acidification by dexamethasone attenuates mitochondrial dysfunction in a human inflammatory proximal tubule epithelial cell model. Sci Rep. 7, 10623 (2017).
23. Koopman WJ, Visch HJ, Smeitink JA, Willems PH. Simultaneous quantitative measurement and automated analysis of mitochondrial morphology, mass, potential, and motility in living human skin fibroblasts. Cytometry A. 69, 1-12 (2006).
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 65, 55-63 (1983).
25. Durr KL, Tavraz NN, Spiller S, Friedrich T. Measuring cation transport by Na,K- and H,K-ATPase in Xenopus oocytes by atomic absorption spectrophotometry: an alternative to radioisotope assays. J Vis Exp. e50201 (2013).
26. Eljack ND, Ma HY, Drucker J, Shen C, Hambley TW, New EJ, Friedrich T, et al. Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. Metallomics. 6, 2126-2133 (2014). 27. Pietruck F, Ullrich KJ. Transport interactions of different organic cations during their excretion by
the intact rat kidney. Kidney Int. 47, 1647-1657 (1995).
28. Cetinkaya I, Ciarimboli G, Yalcinkaya G, Mehrens T, Velic A, Hirsch JR, Gorboulev V, et al. Regulation of human organic cation transporter hOCT2 by PKA, PI3K, and calmodulin-dependent kinases. Am J Physiol Renal Physiol. 284, F293-302 (2003).
29. Hall MD, Telma KA, Chang KE, Lee TD, Madigan JP, Lloyd JR, Goldlust IS, et al. Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. Cancer Res. 74, 3913-3922 (2014).
30. Kawabe T, Chen ZS, Wada M, Uchiumi T, Ono M, Akiyama S, Kuwano M. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett. 456, 327-331 (1999).
31. Ito S, Kusuhara H, Kuroiwa Y, Wu C, Moriyama Y, Inoue K, Kondo T, et al. Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther. 333, 341-350 (2010).
32. Atilano-Roque A, Aleksunes LM, Joy MS. Bardoxolone methyl modulates efflux transporter and detoxifying enzyme expression in cisplatin-induced kidney cell injury. Toxicol Lett. 259, 52-59 (2016).
33. Aleksunes LM, Goedken MJ, Rockwell CE, Thomale J, Manautou JE, Klaassen CD. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J Pharmacol Exp Ther. 335, 2-12 (2010).
34. Huang D, Wang C, Duan Y, Meng Q, Liu Z, Huo X, Sun H, et al. Targeting Oct2 and P53: Formononetin prevents cisplatin-induced acute kidney injury. Toxicol Appl Pharmacol. 326, 15- 24 (2017).
35. Shu Y, Bello CL, Mangravite LM, Feng B, Giacomini KM. Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells. J Pharmacol Exp Ther. 299, 392-398 (2001).
72
36. Fukuda Y, Kaishima M, Ohnishi T, Tohyama K, Chisaki I, Nakayama Y, Ogasawara-Shimizu M, et al. Fluid shear stress stimulates MATE2-K expression via Nrf2 pathway activation. Biochem Biophys Res Commun. 484, 358-364 (2017).
37. Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, et al. A phosphotyrosine switch regulates organic cation transporters. Nat Commun. 7, 10880 (2016).
38. Ahn SY, Jamshidi N, Mo ML, Wu W, Eraly SA, Dnyanmote A, Bush KT, et al. Linkage of organic anion transporter-1 to metabolic pathways through integrated “omics”-driven network and functional analysis. J Biol Chem. 286, 31522-31531 (2011).
39. Wu W, Jamshidi N, Eraly SA, Liu HC, Bush KT, Palsson BO, Nigam SK. Multispecific drug transporter Slc22a8 (Oat3) regulates multiple metabolic and signaling pathways. Drug Metab Dispos. 41, 1825-1834 (2013).
40. Nigam SK. What do drug transporters really do? Nat Rev Drug Discov. 14, 29-44 (2015). 41. Bush KT, Wu W, Lun C, Nigam SK. The drug transporter OAT3 (SLC22A8) regulates endogenous
metabolite flow through the gut-liver-kidney axis. J Biol Chem. 292, 15789-15803 (2017). 42. Kaufhold M, Schulz K, Breljak D, Gupta S, Henjakovic M, Krick W, Hagos Y, et al. Differential
interaction of dicarboxylates with human sodium-dicarboxylate cotransporter 3 and organic anion transporters 1 and 3. Am J Physiol Renal Physiol. 301, F1026-1034 (2011).
43. Burckhardt BC, Burckhardt G. Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 146, 95-158 (2003).
44. Sweet DH, Chan LM, Walden R, Yang XP, Miller DS, Pritchard JB. Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient. Am J Physiol Renal Physiol. 284, F763-769 (2003).
45. Nagai J, Yano I, Hashimoto Y, Takano M, Inui K. Efflux of intracellular alpha-ketoglutarate via p-aminohippurate/dicarboxylate exchange in OK kidney epithelial cells. J Pharmacol Exp Ther. 285, 422-427 (1998).
46. Budiman T, Bamberg E, Koepsell H, Nagel G. Mechanism of electrogenic cation transport by the cloned organic cation transporter 2 from rat. J Biol Chem. 275, 29413-29420 (2000).
47. Okuda M, Urakami Y, Saito H, Inui K. Molecular mechanisms of organic cation transport in OCT2- expressing Xenopus oocytes. Biochim Biophys Acta. 1417, 224-231 (1999).
48. Zalups RK. Molecular interactions with mercury in the kidney. Pharmacol Rev. 52, 113-143 (2000).
49. Zalups RK. Evidence for basolateral uptake of cadmium in the kidneys of rats. Toxicol Appl Pharmacol. 164, 15-23 (2000).
50. Cannon VT, Zalups RK, Barfuss DW. Amino acid transporters involved in luminal transport of mercuric conjugates of cysteine in rabbit proximal tubule. J Pharmacol Exp Ther. 298, 780-789 (2001).
51. Starokozhko V, Vatakuti S, Schievink B, Merema MT, Asplund A, Synnergren J, Aspegren A, et al. Maintenance of drug metabolism and transport functions in human precision-cut liver slices during prolonged incubation for 5 days. Arch Toxicol. 91, 2079-2092 (2017).
52. Schneider R, Meusel M, Betz B, Held C, Moller-Ehrlich K, Buttner-Herold M, Wanner C, et al. Oat1/3 restoration protects against renal damage after ischemic AKI. Am J Physiol Renal Physiol. 308, F198-208 (2015).
53. Liu T, Meng Q, Wang C, Liu Q, Guo X, Sun H, Peng J, et al. Changes in expression of renal Oat1, Oat3 and Mrp2 in cisplatin-induced acute renal failure after treatment of JBP485 in rats. Toxicol Appl Pharmacol. 264, 423-430 (2012).
54. Shaw G, Morse S, Ararat M, Graham FL. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. Faseb j. 16, 869-871 (2002).
55. Van der Hauwaert C, Savary G, Buob D, Leroy X, Aubert S, Flamand V, Hennino MF, et al. Expression profiles of genes involved in xenobiotic metabolism and disposition in human renal tissues and renal cell models. Toxicol Appl Pharmacol. 279, 409-418 (2014).
3
56. Wilmer MJ, Ng CP, Lanz HL, Vulto P, Suter-Dick L, Masereeuw R. Kidney-on-a-Chip Technology forDrug-Induced Nephrotoxicity Screening. Trends Biotechnol. 34, 156-170 (2016).
57. Chu X, Bleasby K, Evers R. Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin Drug Metab Toxicol. 9, 237-252 (2013). 58. Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, et al. Discovery of potent,
selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem. 56, 781-795 (2013). 59. Tsuda M, Terada T, Asaka J, Ueba M, Katsura T, Inui K. Oppositely directed H+ gradient functions
as a driving force of rat H+/organic cation antiporter MATE1. Am J Physiol Renal Physiol. 292, F593-598 (2007).
60. Andersson A, Ehrsson H. Stability of cisplatin and its monohydrated complex in blood, plasma and ultrafiltrate--implications for quantitative analysis. J Pharm Biomed Anal. 13, 639-644 (1995).
61. Jennerwein M, Andrews PA. Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II). Drug Metab Dispos. 23, 178-184 (1995).
74
Supplemental data
Supplemental Figure S3.1 Glutathione content is similar in ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3. Evaluation of whole-cell total glutathione content in ciPTEC-parent, ciPTEC-OAT1 and
ciPTEC-OAT3. Results are normalized to ciPTEC-parent (mean±S.E.M., n=3; no significant differences were found by one-way ANOVA).
Supplemental Table S3.1 Gene expression of OCT2 and MATE1/2-k is differentially regulated between ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3. Ct values (A.U.) of OCT2, MATE1 and
MATE2-k derived from RT-qPCR assays following SFM exposure for 24 h are within the quantifiable range and are differentially regulated between ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3 (mean Ct±S.E.M., n=3).
ciPTEC-parent ciPTEC-OAT1 ciPTEC-OAT3
GAPDH 17.7 ± 0.1 17.9 ± 0.1 17.3 ± 0.1 OCT2 (SLC22A2) 33.6 ± 0.2 35.0 ± 0.4 34.8 ± 0.2 MATE1 (SLC47A1) 28.4 ± 0.3 24.6 ± 0.1 25.5 ± 0.1 MATE2-k (SLC47A2) 31.9 ± 0.3 30.1 ± 0.3 32.5 ± 0.3
Supplemental Table S3.2 Gene expression of MRP2 is not differentially regulated between ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3. Ct values (A.U.) of MRP2 derived from RT-qPCR
assays following SFM exposure for 24 h are not differentially regulated between ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3 (mean Ct±S.E.M., n=3).
ciPTEC-parent ciPTEC-OAT1 ciPTEC-OAT3
GAPDH 18.0 ± 0.2 18.2 ± 0.5 16.8 ± 0.4 MRP2 (ABCC2) 33.1 ± 0.6 33.2 ± 0.6 31.6 ± 0.3
76